Trial Profile

Cemiplimab Treatment in Patients With Locally Advanced and Metastatic Secondary Angiosarcomas

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary)
Indications Haemangiosarcoma
Focus Therapeutic Use
Acronyms CEMangio

Most Recent Events

31 Oct 2024 Status changed from recruiting to completed.
04 Jun 2024 Results (At the cutoff date 23-Jan-24) assessing safety and efficacy of Cemiplimab in locally advanced and/or metastatic secondary angiosarcomas presented at the 60th Annual Meeting of the American Society of Clinical Oncology
19 Jan 2022 Planned primary completion date changed from 1 May 2024 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com